Koers MYND Life Sciences Inc. OTC Markets
Aandelen
MYND.F
CA62857B1094
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,0249 USD | +17,45% | -.--% | -20,19% |
Omzet 2022 | - | Omzet 2023 | - | Marktkapitalisatie | 717K 661K |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -3 mln. -2,77 mln. | Nettowinst (verlies) 2023 | -1 mln. -922K | EV/omzet 2022 | - |
Nettoschuld 2022 | 2,59 2,38 | Nettoschuld 2023 | 3 2,77 | EV/omzet 2023 | - |
K/w-verhouding 2022 |
-1,05
x | K/w-verhouding 2023 |
-0,47
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 40,17% |
1 dag | +17,45% | ||
1 maand | +17,45% | ||
3 maanden | +45,61% | ||
6 maanden | +24,50% | ||
Lopend jaar | -20,19% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
John Campbell
CEO | Chief Executive Officer | 53 | 26-11-20 |
Lyle Oberg
FOU | Founder | 63 | 06-07-18 |
Founder | 65 | 06-07-18 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 65 | 06-07-18 | |
Lyle Oberg
FOU | Founder | 63 | 06-07-18 |
John Campbell
CEO | Chief Executive Officer | 53 | 26-11-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+11,91% | 118 mld. | |
+11,60% | 106 mld. | |
-4,68% | 24,28 mld. | |
-0,82% | 21,96 mld. | |
-10,12% | 18,16 mld. | |
-42,12% | 16,37 mld. | |
-17,47% | 15,56 mld. | |
+2,77% | 13,63 mld. | |
+34,58% | 12,27 mld. |
- Beurs
- Aandelen
- Koers MYND
- Koers MYND.F